Credit Suisse’s Prelude Therapeutics PRLD Stock Holding History

Credit Suisse’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6	Closed	–	–	4224
2022 Q2	$0	Buy	+6	New	+$31	﹤0.01%	4223
2021 Q4	–	Sell	-6,950	Closed	-$216K	–	4641
2021 Q3	$216K	Buy	+6,950	New	+$225K	﹤0.01%	4206

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's PRLD Position: Q3 2022 in Review

Credit Suisse sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 6 shares.

Credit Suisse first reported a position in PRLD in Q3 2021 and held it in 2 quarters. The position peaked at $216K in Q3 2021. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

Credit Suisse reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 6 Prelude Therapeutics shares in Q3 2022.
Credit Suisse first reported a position in Prelude Therapeutics in Q3 2021 and held it in 2 quarters.
Credit Suisse's Prelude Therapeutics position peaked at $216K in Q3 2021.
53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.